Randomized trial · people

Liraglutide: 13.0% vs 14.9% major cardiovascular events in LEADER

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In people with type 2 diabetes and high heart risk, liraglutide lowered the combined rate of heart-related death, heart attack and stroke compared with placebo over a median of 3.8 years.

Kind
Randomized trial
Studied in
People
Number studied
9340
Published
2016
Journal
N Engl J Med

What they tested

The team tested whether adding liraglutide to usual care in type 2 diabetes was at least as safe for the heart as placebo, and whether it lowered heart events.

How the study was done

A double-blind, randomized, placebo-controlled trial (placebo, a dummy treatment) in 9340 people with type 2 diabetes and high cardiovascular risk, followed for a median of 3.8 years. The main outcome was the first of three events: death from cardiovascular causes, a nonfatal heart attack (myocardial infarction) or a nonfatal stroke.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking liraglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

The main outcome occurred in 608 of 4668 people on liraglutide (13.0%) and 694 of 4672 on placebo (14.9%), a hazard ratio of 0.87 (95% CI 0.78 to 0.97). This met the bar for being no worse than placebo (P<0.001) and also for being better (P=0.01). Cardiovascular death was lower with liraglutide (4.7% vs 6.0%; hazard ratio 0.78), and so was death from any cause (8.2% vs 9.6%; hazard ratio 0.85). Nonfatal heart attack, nonfatal stroke and hospital stays for heart failure were lower with liraglutide, but not significantly, and gastrointestinal events were the most common reason people stopped the drug.

What it doesn’t show

The trial only enrolled people with type 2 diabetes at high cardiovascular risk, and the prespecified exploratory outcomes were not adjusted for testing many outcomes at once. It was funded by Novo Nordisk and the National Institutes of Health.

The paper

Marso et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016.

The compound

More studies on Liraglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking liraglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo